Patrick Derigs, MD, University Hospital Heidelberg, Heidelberg, Germany, talks on the potential role of chimeric antigen receptor T-cell (CAR-T) therapy in patients with chronic lymphocytic leukemia (CLL) with high-risk genetic abnormalities. Dr Derigs explains that in this difficult-to-treat patient population with few effective therapeutic options, CAR-T therapy represents a promising treatment strategy. However, there are still many concerns over the efficacy and durability of CAR-Ts in CLL. Third-generation retroviral vector-transduced CAR-Ts could help overcome these challenges. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.